

Phyllanthin: A Potential Lead Molecule for the Future Needs

Mohammed Azam*, Makula Ajitha

Center for Pharmaceutical Sciences, Institute of Science and Technology, JNTUH, Hyderabad, Telangana-500085, India

Received: 25th June, 17; Revised 24th July, 17, Accepted: 15th Aug, 7; Available Online: 25th Aug, 17

ABSTRACT

Phyllanthin is an active lignan present in various *Phyllanthus* species and number of studies revealed that it exhibits various biological activities that include antioxidant, hepatoprotective, anticancer, antidiabetic, immunosuppressant and anti-inflammatory activities. After thorough examination of existing literature it was discovered that there is currently no comprehensive review available on this significant phytochemical. Hence, an attempt was made to present the physicochemical properties, enhancement techniques of yield and bioavailability, synthesis, pharmacological applications and toxicity studies of phyllanthin. This report also highlights semisynthetic derivatives and mechanisms of action of phyllanthin for various biological activities.

Keywords: *Phyllanthus*, *Phyllanthus amarus*, lignan, hepatoprotective, anticancer, semisynthetic derivatives, bioavailability.

INTRODUCTION

Natural products, mainly the plant-derived constituents, have long been sources of drugs. There are number of advantages using plants and phytoconstituents compared to pharmaceuticals available in modern medicine. Several classes of secondary metabolites are synthesized by plants and, among those, lignans are recognized as a class of natural products with a wide spectrum of important biological activities. The term "Lignan" was first introduced by Haworth (1948) to describe a group of dimeric phenyl propanoids (Fig-1) where two C6-C3 are attached by its central carbon (C8), as shown in Figure-2. Aromatic amino acids L-phenylalanine and L-tyrosine are produced from shikimic acid pathway, and then converted into a series of cinnamic acid derivatives further reduction of these acids via coenzyme A forms three alcohols p-coumaryl alcohol, coniferyl alcohol and sinapyl alcohol, which act as main precursors for all lignans¹. Lignans exist abundantly in the *Phyllanthus* genus, which consist of more than 600 species of shrubs, trees and rare herbs belong to the Euphorbiaceae family.

Phyllanthin is the major therapeutically active lignan present in various *Phyllanthus* species such as *Phyllanthus amarus* (*Phyllanthus niruri*), *Phyllanthus urinaria*, and *Phyllanthus maderaspatensis* etc. A number of studies proved that phyllanthin possess hepatoprotective activity against carbon tetrachloride, galactosamine and ethanol treatment^{2,3,4}. It was revealed that phyllanthin effectively acts against diabetes and various chemical and virus induced liver abnormalities including hepatitis⁵, antifibrotic⁶ and anti-inflammatory⁷. Phyllanthin is also known to possess immunomodulatory⁸, nephroprotective⁹, and anticancer¹⁰ properties. After thorough examination of existing literature it was discovered that there is currently no comprehensive review available on this significant

phytochemical. The purpose of this review is to deliver a comprehensive update on the status of the research carried out on the Phyllanthin in the fields of pharmacognostical, physicochemical and pharmacological.

Phyllanthin

Phyllanthin (Fig-3) chemically known as (4-[(2S, 3S)-3-[(3, 4-dimethoxyphenyl) methyl]-4-methoxy-2-(methoxymethyl) butyl]-1, 2-dimethoxybenzene). Molecular formula and molecular weight of phyllanthin was found to be C₂₄H₃₄O₆ and 418.51 respectively. It is a diaryl butane type lignan linked through C8-C8' of phenyl propanoid units. The stereochemistry in phyllanthin was identified as 8(S), 8'(R). A single crystal X-ray analysis revealed the full 3-dimensional structural characterization of phyllanthin¹¹.

Phyllanthin obtained from plants belongs to *Phyllanthus* species. It was also synthesized in laboratory using (+) 2, 3-diveratryl succinic acid and resolution was secured through its cinchonine salt¹².

Physicochemical properties

Phyllanthin showed maximum UV absorbance at two wavelengths, 230nm and 280 nm, displayed IR spectrum vibrations at 2999, 2917 and 2868 cm⁻¹ (C-H aliphatic stretch); 1516 and 1464 cm⁻¹ (C=C ring stretch) and 1141 cm⁻¹ (C-O-C stretch) and shown molecular ion peak in MS spectrum at 418 m/z and a base peak at 151 m/z. Phyllanthin crystals showed the melting point and melting enthalpy range of 96.67–97.03 °C and 109.61–116.34 J/g, respectively. Crystals, recrystallized from petroleum ether, absolute ethanol and 25% ethanol solution, revealed only one polymorph and no polymorphic impurity and 25% ethanol solution gave high crystallinity. Its thermal decomposition was found to be above 200 °C. It has stability in aqueous solution over a pH range of 1.07–10.02 for at least 4 h and expected to be unaffected by the

*Author for Correspondence: mohammed.azam504@gmail.com

variation in pH throughout the GI tract. Solubility was found to be in the range of 7.32–8.57 mg/ml and appeared to be pH-independent and it has no pKa over a pH range of 1.12–10.02. The log P_{ow} value was found to be 3.30 ± 0.05 at pH 7.48 by shake flask method, it indicates good permeability through biological membranes¹³.

Enhancement of yield

Considering the importance of Phyllanthin various researchers tried to increase its yield by using various techniques.

By using different harvesting techniques

Phyllanthin content was observed more in plants growing at higher altitudes as compared to lower altitude¹⁴. When three areas having different soil, profile and color taken it is revealed that the content of the phyllanthin does not fluctuate significantly and are not very much dependent on any biotic or abiotic factor in particular to enhance or decrease them¹⁵. A study was carried out to know the effect of Nitrogen, magnesium and shading revealed that 2.39 g of urea and 0.48 g of MgSO₄ per plant and 3 months of harvest produced the highest phyllanthin yield¹⁶. It was revealed that heavy metals such as chromium and cadmium at certain level enhance concentration of secondary metabolite phyllanthin in *Phyllanthus amarus* due to abiotic stress^{17,18}.

By genetically modifying

When transgenic lines and wild plants was compared using HPLC it was discovered that transgenic lines contained higher phyllanthin content (0.3–0.81% w/w) than wild plants (0.09% w/w)¹⁹. CIM-Jeevan a cultivar of *Phyllanthus amarus* plant producing high amount phyllanthin and hypophyllanthin was developed by using γ -irradiation of superior germ plasm²⁰.

By using biotechnology

A study depicted enhancement of phyllanthin yield by immobilization technique, HPTLC was used to compare the phyllanthin contents in calcium alginate immobilized cells obtained from fresh grown plants and MS medium was supplemented with different abiotic elicitors. The study revealed that an increase in the content of phyllanthin and hypophyllanthin were elicitor concentration dependent and silver nitrate treatment gave a maximum yield of hepatoprotective bioactives as compared to the other abiotic elicitors used²¹. Another immobilization technique developed to enhance phyllanthin and hypophyllanthin by using calcium alginate immobilized cells obtained from fresh grown plants and M. S. medium which was supplemented with different precursors and phytohormones. It was revealed that cinnamic acid treatment gave maximum yield of hepatoprotective bioactives as compared to other precursor and phytohormones²².

An experiment performed on callus by manipulating the different concentrations of phytohormones revealed that 12 week old callus culture induced in MS media containing phytohormones 2, 4-D (1mg/L) and Kinetin (0.5mg/L) gave the maximum yield of phyllanthin (0.805%)²³. When thidiazuron is used in Murashige and Skoog (MS) medium caused the regenerated shoots to produce about two time's higher phyllanthin and hypophyllanthin than the leaves of

naturally grown plant²⁴. When MS medium containing callus was treated with gibberellin acid, coconut water, sugarcane juice and water-melon extract and estimated by HPTLC it was revealed that watermelon extract, enhances maximum phyllanthin yield followed by sugarcane juice, coconut water and gibberellin acid²⁵.

A research work found an endophytic fungi from different parts of *Phyllanthus amarus* producing bioactive compounds phyllanthin and hypophyllanthin²⁶. A team developed micropropagation method to overcome the uncertainty in stable supply by the hyperproducing ecotype which was able to produce phyllanthin in good yield²⁷. In a study cDNA library from fresh young leaves of *Phyllanthus amarus* was created and used it for generation of EST database to explore the presence of metabolite synthesizing enzymes in the library. This EST's can be used as a first-hand reference at the molecular level to identify the genes of phyllanthin biosynthetic pathway²⁸. Some researchers tried to increase the yield by enhancing phyllanthin extraction from plants by using various methods such as supercritical fluid extraction^{29, 30}, pressurized liquid extraction³¹, soxhlation³², and other conventional methods.

Enhancement of bioavailability

To address the phyllanthin low bioavailability some research had been carried out. a research group developed phyllanthin-loaded self-microemulsifying drug delivery system which contain phyllanthin/capryol 90/cremophor RH 40/transcutol P in ratio of (1.38:39.45:44.38:14.79) w/w resulted very good enhancement of solubility, in-vitro release and in-vivo oral bioavailability in rats compared with pure phyllanthin³³. Conventional and PEGylated liposomes of phyllanthin were developed through film hydration technique. Extended drug release for over 24 h was observed in in-vitro drug release studies³⁴. By using coacervation technique phyllanthin containing chitosan based microcapsules were developed and more than 60% of phyllanthin released after 120h. This microcapsules showed enhanced growth inhibitory activity towards *Staphylococcus aureus* and stronger anti-oxidation potential on both human fibroblasts and keratinocytes³⁵. A mixed micellar lipid formulation (MMLF) of Phyllanthin along with piperine by using phosphatidylcholine was formulated to increase the bioavailability and hepatoprotective activity against CCl₄ damaged hepatotoxicity. The complex MMLF normalized adverse conditions of rat livers more efficiently than the non-formulated phyllanthin. The present findings indicate that the MMLF is helpful in solving the problem of low bioavailability of phyllanthin³⁶.

Semisynthetic derivatives

To further enhance the potential of phyllanthin, derivatives were prepared by some groups. Bromo derivative of phyllanthin was synthesized and along with phyllanthin, it was tested for curative impact on cythion induced activities in albino rats with special reference to blood serum (VLDL, LDL, and HDL) hepatotoxicity. The results reveals that there is a declining trend in the values of these constituents in cythion treated albino rats. Administration of phyllanthin and Bromo derivative phyllanthin showed

remarkable curative effect³⁷. Dibromophyllanthin was synthesized and characterized by NMR³⁸. Iodo derivative of phyllanthin was synthesized and characterized by x-ray crystallography³⁹. Around 28 derivatives of phyllanthin were synthesized and evaluated for anti-HIV activities. Four compounds showed good anti-HIV activity⁴⁰.

Nano particles synthesis: It was found that phyllanthin is able to help in the synthesis of nanoparticles. A simple and efficient way for the production of anisotropic gold and silver nano particles using the phyllanthin extract was established. HAuCl₄ greatly reduced by phyllanthin than AgNO₃ at constant amount. Phyllanthin -OCH₃ group plays an important role in formation and stabilization of nano particles by donating the electrons and interacting with metal ions⁴¹. A green, high-yield, fast, and low-cost approach was made to reduce silver ions to nano sized silver particles by using plant broth of *Phyllanthus amarus* containing phyllanthin. Plasmon absorbance of silver nanoparticles was proven by UV-visible spectrum⁴².

Pharmacokinetics

A study was evaluated the pharmacokinetic parameters of phyllanthin in rat plasma after intravenous and oral administration. Results revealed that after intravenous administration, phyllanthin showed a gradual decline in its plasma concentrations and estimated volume of distribution (V_d) of the phyllanthin was relatively small with a mean value of 0.20 l/kg shows that it was not widely distributed into the tissue compartment. Phyllanthin appeared to be cleared slowly from the body as evidenced by its small mean clearance values of 0.04 l/kg h. Following an oral administration, phyllanthin showed a rapid rise with a T_{max} of 1 h followed by a gradual decline to 0 after 24 h. Mean C_{max} values was 0.18 µg/ml. The calculated absolute bioavailability found to be 0.62%. The low oral bioavailability may be due to its poor aqueous solubility causing only a small fraction available in dissolved form for absorption after oral administration⁴³.

Pharmacological activities

The scientific literature revealed that phyllanthin has been reported to possess the antioxidant, hepatoprotective and various other activities such as anticancer, anti-inflammatory, antifibrotic, vasodilator, anti-microbial, immunomodulatory effects and anti-diabetic activity etc.,

Antioxidant

Aqueous extract of *Phyllanthus amarus* whole plant possesses an effective in vitro antioxidant activity, which may be due to radical-scavenging & reducing power. This effect attributed to the total phenolics, among which phyllanthin and hypophyllanthin is regarded as important bioactive compounds⁴⁴. A study revealed that lignan phyllanthin is responsible for radioprotector activity of *Phyllanthus niruri* by scavenging free radicals⁴⁵.

Hepatoprotective

Phyllanthin shown hepatoprotective activity against CCL₄, galactosamine and alcohol induced hepatitis.

Against CCL₄

A combination therapy containing silymarin and standardized extract of *Phyllanthus amarus* tested against CCl₄-induced hepatotoxicity in rats and it showed synergistic effect for hepatoprotection. This improved

activity with ethanolic extract of *Phyllanthus amarus* due to the higher concentration of phyllanthin in ethanolic extract than aqueous extract of *Phyllanthus amarus* as estimated by HPLC².

A research group evaluated the hepatoprotective and antioxidative property *Phyllanthus amarus* extract by invitro techniques⁴⁶ (DPPH assay and human hepatoma HepG2 cell line) and invivo mice model⁴⁷. The results indicated that phyllanthin effectively alleviated the changes induced by CCl₄ in a concentration-dependent manner, with much smaller strengths as compared to *Phyllanthus amarus* extract and lowered 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) metabolism and increased the release of transaminases which were adjusted with co-incubation with *Phyllanthus amarus*. Even Histopathology and ultramicroscopic studies correlated well with the biochemical findings, as phyllanthin treatment reversed the alterations induced by the toxin and the subcellular features of phyllanthin treated mice were similar to those present in the normal mouse liver. Study suggested that in vivo anti-hepatotoxic potential of phyllanthin may be responsible for the liver protecting property of *Phyllanthus amarus*⁴⁸.

Protective effects and possible mechanism of phyllanthin was investigated against carbon tetrachloride (CCl₄)-induced hepatic damage in common carp. The results showed that administration of phyllanthin inhibited the adverse changes caused by CCl₄ in serum and liver tissue and data from histopathology also suggested that phyllanthin may be used as a hepatoprotective agent to prevent liver diseases in fish⁴⁹. Oral pre-treatment of phyllanthin at a dose of 120 mg/kg prior to CCl₄-treatment effectively prevented the hepatic damage by reducing alanine aminotransferase (ALT) and aspartate aminotransferase (AST)⁵⁰.

Against Galactosamine-induced

Phyllanthin and hypophyllanthin isolated from a hexane extract of *Phyllanthus niruri* along with two other constituents protected against carbon tetrachloride- and galactosamine-induced cytotoxicity in primary cultured rat hepatocytes³. Protective mechanism of lignans from *Phyllanthus amarus* against galactosamine/lipopolysaccharide-induced hepatitis in mice was evaluated and correlated it from in-silico molecular docking studies. In-vivo and in-silico results suggest that pretreatment of standardize mixture of lignans exhibit potent hepatoprotection against galactosamine/lipopolysaccharide -induced hepatitis in mice and the liver protective effects may be due to the inhibition of inflammatory mediators⁵¹.

Against Alcohol induced

Alcohol induces oxidative stress when taken at higher concentrations and along with polyunsaturated fatty acid (PUFA) elevated lipid peroxidative products and antioxidant defense potential lost greatly. An experiment was carried on alcohol and heated PUFA induced hepatotoxicity shown that *Phyllanthus niruri* effectively decreased the oxidative stress and associated damage and it was hypothesized that phyllanthin along with other




Figure 1: Phenylpropanoid.




Figure 2: Lignan structure.




Figure 3: Phyllanthin.


 Figure 4: *Phyllanthus* species.

compounds was responsible for this effect⁴. Protective effect of phyllanthin was investigated against ethanol-induced rat liver cell injury. Phyllanthin antagonized the ethanol-induced oxidative stress and restored the antioxidant capability of rat hepatocytes along with level of total glutathione, and activities of superoxide dismutase (SOD) and glutathione reductase (GR) which were reduced by ethanol. Results suggested that hepatoprotective effect of phyllanthin against ethanol was due to its antioxidant activity⁵².

Anti-HBV

Different extracts from *Phyllanthus rheedei* were evaluated for Anti-HBV activity by using PLC/PRF, Hep3B, FLCII10 and HepG2215 cell lines and analysis was done by using ELISA, SQRT-PCR and immuno blotting techniques. From the screening experiments it was shown that the ethanol extract of this plant has the maximum activity in lowering the viral markers like hepatitis-B surface antigen (HBsAg), HBV Core and HBV X protein and whole virions with comparatively lesser cytotoxicity. The dose responses of this particular extract were further established. The ethanol extract was then evaluated by using HPTLC revealed the presence of phyllanthin, hypophyllanthin, ellagic acid and Quercetin and it was proved through standards⁵³.

Anticancer

Preventive and curative role of *Phyllanthus amarus* lignans was examined in tumor bearing mice by taking a mixture (1:1) of phyllanthin and hypophyllanthin. Antitumor activities against Ehrlich ascites carcinoma in the Swiss albino mice was proved by the decrement of tumor volume, and packed cell volume and viable cell count were observed in lignans treated mice. Treatment with test compounds increased the survival time and normal peritoneal cell count⁵⁴. Antigenotoxic property of a crude extract of *Phyllanthus amarus L* was proved by

using two types of tannery effluents. The root meristems was pre-treated with effluents caused the maximum incidence of mitotic anomalies, were then exposed to the crude extract of *Phyllanthus amarus* showed a significant reduction in the frequency of chromosomal alterations⁵⁵. Multidrug resistance constitutes the major obstacle to the successful treatment of cancer and it is thought to be mediated by the super-expression of P-glycoprotein (Pgp). Pgp extrudes drugs from the cells, therefore reducing their cytotoxicity, and its activity inhibition may reverse the MDR phenotype. Lignans from *Phyllanthus amarus* reversed the cytotoxic effect and the multidrug resistance (MDR). Results revealed that along with other compounds phyllanthin also showing a potent action as MDR reversing agents, mainly due to their ability to synergize with the action of conventional chemotherapeutics⁵⁶.

Anti-inflammatory

Chondroprotective potential of *Phyllanthus amarus* extract and its lignans, phyllanthin and hypophyllanthin was evaluated in experimental cartilage explant degradation model induced by IL-1 β . They show decrease in sulfate glycosaminoglycans level and matrix metalloproteinase-2 activity in culture medium consistent with an increase in uronic acid and proteoglycan contents in the explants when compared to the IL-1 β treatment. Improved activity was observed in *Phyllanthus amarus* crude extracts than those of the purified components⁷. Hexanic extract of *Phyllanthus amarus* containing phyllanthin, niranthin, and 5-demethoxyniranthin did not show antihypernociceptive activity in experimental autoimmune encephalomyelitis⁵⁷. Protective effect of phyllanthin and hypophyllanthin was examined against colitis model of inflammatory bowel disease in Wistar rats showed that *Phyllanthus amarus* exert a preventive anti-inflammatory, antioxidant and anti-apoptotic effect by the neutrophil infiltration inhibition, inhibition of pro-inflammatory mediator production and

reducing DNA damage due to the presence of phyllanthin and hypophyllanthin phytoconstituents⁵⁸.

Study designed to evaluate anti-arthritic activity of *Phyllanthus amarus* extract containing 2.5% phyllanthin and hypophyllanthin against Freund's complete adjuvant induced arthritic rats and it was revealed that extract mitigated the changes brought by arthritis and suggested that it has prominent anti-arthritic activity⁵⁹. An in vitro study suggested that the anti-inflammatory activity of *Phyllanthus simplex* petroleum ether extract (PSPE) and *Phyllanthus simplex* ethanol extract (PSEE) was mediated by their inhibitory action on NO production in a dose dependent manner ($p < 0.05$) and based on previous studies they concluded that phyllanthin and gallic acid were present in extract responsible for its anti-inflammatory activity by controlling NO production⁶⁰.

Antifibrotic

Chronic injury to liver causes synthesis of extracellular matrix components resulting in progressive fibrosis and eventually cirrhosis. Transforming growth factor- β 1 (TGF- β 1) transduces its signal by binding to TGF- β type 1 receptor kinase or activin like kinase (ALK5) receptor and mediates hepatic fibrosis by increasing the transcription of downstream entities such as collagen via Smad₂ and Smad₃. Antifibrotic potential of phyllanthin was evaluated against important profibrotic mediator transforming growth factor β 1 and predominant extracellular matrix (ECM) components collagen and fibronectin. The outcomes revealed the molecular mechanism of phyllanthin which acts by suppressing the expression of inflammatory cytokine tumor necrosis factor- α and prevents activation of nuclear factor- κ B in hepatic tissue⁶ and it was correlated by molecular docking experiments, which shown inhibitory role of phyllanthin on TGF- β type 1 receptor kinase⁶¹. Research conducted to examine the antifibrotic activity of *Phyllanthus maderaspatensis* hexane extract (PmHE) in Wistar rats based on preventive and curative treatment strategies revealed that post treatment with PmHE (200 mg/ kg) reversed CCl₄ induced hepatic fibrosis in rats. Analytical methods HPLC and HPTLC were used to confirm the presence of phyllanthin and quercetin. It was hypothesized that mechanism of action may be scavenging the reactive oxygen species, produced from inflammatory cells and liver cells, reducing collagen deposition and down regulating the over expression of α SMA and collagen III at proteins and mRNA levels⁶².

Vasodilator

Modulating effects of phyllanthin and hypophyllanthin on vascular tension was investigated using the in vitro model of isolated rat aorta showed that sustained contraction induced by phenylephrine was significantly relaxed by phyllanthin and hypophyllanthin. It was revealed phyllanthin more active than hypophyllanthin against contractile responses upon cumulative addition of CaCl₂ and mechanism of action may be via the endothelium independent⁶³.

Immunosuppressive effects

A study revealed that the standardized ethanol extract of *Phyllanthus amarus* was able to suppress the immune

response of both specific and nonspecific immunity in Wistar-Kyoto rats through various pathways. Immunosuppressive activity of 80% ethanol extract of *Phyllanthus amarus* in Wistar-Kyoto rats exhibited significant inhibition of the phagocytic activity of neutrophils by down regulation of the percentage of CD11b and CD18 expression in neutrophils, of chemotaxis, and of phagocytosis of *E. coli* by neutrophils. It was shown that phyllanthin and hypophyllanthin were main constituents in extracts, which may be responsible for this activity⁶⁴. Immunosuppressive effects of phyllanthin on cellular and humoral immune responses evaluated by using Balb/C mice. Phyllanthin dose-dependently inhibited CD11b/CD18 adhesion, the engulfment of *E. coli* by peritoneal macrophages molecules, NO and MPO release in treated mice. It was revealed that phyllanthin significantly inhibited T and B lymphocytes proliferation, down-regulated the Th1 (IL-2 and IFN- γ) and Th2 (IL-4) cytokines, reduced the expression of CD4+ and CD8+ in splenocytes and inhibited the sheep red blood cell (sRBC)-induced swelling rate of mice paw in delayed type hypersensitivity⁸.

Immunomodulatory effect of the standardized methanol extracts of *Phyllanthus amarus* and *Phyllanthus urinaria* and their biomarkers phyllanthin and hypophyllanthin was examined. It was found that they were able to modulate the innate immune response of phagocytes especially on the chemotactic migration of phagocytes, phagocytic ability, and on the release of ROS. Phyllanthin exhibited higher inhibitory effects on the phagocytic activity of neutrophils particularly in inhibiting ROS production and bacteria engulfment as compared to hypophyllanthin⁶⁵. Effects of constituents of the extract of *Phyllanthus amarus* on nitric oxide (NO) production as well as lymphocyte proliferation and cytokine release from phagocytes were evaluated. Among the compounds tested, the lignans, especially phyllanthin and phyllanthin, showed strong inhibition on lymphocyte proliferation with half maximal inhibitory concentration (IC₅₀) values of 1.07 μ M and 1.82 μ M, respectively. The compounds constituting the extract of *Phyllanthus amarus* were able to inhibit the innate immune response of phagocytes at different steps⁶⁶.

Antimicrobial

Antimicrobial activity of the methanolic extract of *Phyllanthus amarus* was explored against some drug resistant pathogenic bacterial strains by disc diffusion and agar dilution method. The extract showed significant concentration-dependent antibacterial activity particularly against gram-negative microbes. They showed antibacterial action was mainly due to the isolated phyllanthin⁶⁷.

Antidiabetic

An investigation was done by a group to endorse the ethnopharmacological information of *Phyllanthus niruri* against Type-2 diabetes mellitus (T2DM) through molecular docking and pharmacophore modeling. They found that phyllanthin had affinity for aldose reductase and can be used against T2DM⁶⁸.

Antihyperuricemic

Oral antihyperuricemic activity of lignans was evaluated in potassium oxonate and uric acid-induced hyperuricemic rats. Study revealed that among isolated lignans phyllanthin significantly reversed the plasma uric acid level of hyperuricemic animals to its normal level in a dose-dependent manner, comparable to that of allopurinol, benzbromarone, and probenecid which are used for the treatment of hyperuricemia and gout⁶⁹. Mechanism for antihyperuricemic effect was investigated by using xanthine oxidase assay and uricosuric studies in potassium oxonate and uric acid induced hyperuricemic rats. Results showed that methanol extract exhibited in vitro xanthine oxidase inhibition and a moderate in vivo xanthine oxidase inhibitory activity. However, the lignans display poor xanthine oxidase inhibition in vitro and a relatively weak in vivo inhibitory activity whereas intraperitoneal treatment with methanol extract and lignans, phyllanthin, hypophyllanthin and phytetralin exhibited higher urinary uric acid excretion and clearance. It was revealed that methanol extract acting via both uricosuric action and xanthine oxidase inhibition, whereas lignans were acting through uricosuric action only⁹.

Miscellaneous

Effect of phyllanthin and hypophyllanthin on the functioning of P-glycoprotein (P-gp) and multidrug resistance protein 2 (MRP2) was explored using the in-vitro model of Caco-2 cells. Fluorescence spectroscopy used to determine the activity and it was revealed that hypophyllanthin and phyllanthin inhibited P-gp function, but neither compound affected MRP2 activity. It was proved that both phyllanthin and hypophyllanthin could reversibly inhibit P-gp function⁷⁰. Acute toxicity of standardized methanolic extract of *Phyllanthus amarus* (MEPA) was evaluated by using female albino rats. Outcome revealed that phyllanthin and hypophyllanthin were safe⁷¹. Estrogenic properties of phyllanthin and hypophyllanthin against carbofuran induced toxicity in female rats was studied by inducing toxicity with carbofuran on estrous cycle in virgin Wistar rats and recovery from the damaged estrous cycle with treatment of *Phyllanthus amarus* lignans viz. phyllanthin and hypophyllanthin. It was known that phyllanthin and hypophyllanthin transformed into enterolignan(s) systemically, which is expected to be responsible for augmenting estrus cycle in rats⁷². A study evaluated the role of phyllanthin, extracts and some other active constituents against β -glucuronidase inhibitory action. It was revealed that phyllanthin and hypophyllanthin show their hepatoprotective effect through a mechanism other than of β -glucuronidase inhibition⁷³. Mechanism of inhibitory effect of *Phyllanthus amarus* and its major lignans on human microsomal cytochrome P450 was evaluated by using human liver microsomes and selective substrates. It was revealed that phyllanthin and hypophyllanthin were potent mechanism based inhibitors of CYP3A4. The study suggested that co-administration of *Phyllanthus amarus* with drugs that are metabolized by CYP3A4 may potentially result in herb-drug interactions⁷⁴.

CONCLUSION

Phyllanthin is a major active lignin which exists in various *Phyllanthus* species and it exhibits various biological activities. It shows significant hepatoprotective, anticancer, antidiabetic, immunosuppressant, anti-inflammatory and various other activities. Physicochemical properties, various yield and bioavailability enhancement techniques, biosynthesis, synthetic route, pharmacological applications, mechanism of action, herb-drug interactions, toxicity studies and semisynthetic derivatives of phyllanthin has been discussed. This review is presented in view of immense importance of phyllanthin in the health care system. Further research by taking phyllanthin as lead molecule will have great scope. Further development of safe, simple and economic extraction and isolation techniques, laboratory synthesis and derivatives by exploring the structure activity relationship of phyllanthin for the prevalent and rare health problems will be useful for the future needs.

ACKNOWLEDGMENT

This work received financial support from University Grants Commission (UGC) under the Maulana Azad National Fellowship (MANF) scheme, Government of India. We are thankful to UGC, New Delhi for Fellowship.

REFERENCES

1. Cunha WR, e Silva ML, Veneziani RC, Ambrósio SR, Bastos JK. Lignans. *Phytochemicals-A Global Perspective of their Role in Nutrition and Health*. Edn 1, Vol. 1, InTech Croatia, 2012, 213-234.
2. Yadav NP, Pal A, Shanker K, Bawankule DU, Gupta AK, Darokar MP, Khanuja SP. Synergistic effect of silymarin and standardized extract of *Phyllanthus amarus* against CCl₄-induced hepatotoxicity in *Rattus norvegicus*. *Phytomedicine*. 2008; 15(12):1053-61.
3. Syamasundar KV, Singh B, Thakur RS, Husain A, Yoshinobu K, Hiroshi H. Antihepatotoxic principles of *Phyllanthus niruri* herbs. *Journal of ethnopharmacology*. 1985; 14(1):41-4.
4. Baskaran MA, Periyasamy LA, Rajagopalan RU. Effect of *Phyllanthus niruri* on alcohol and polyunsaturated fatty acid induced oxidative stress in Liver. *Int J Pharm Pharm Sci*. 2010; 2(4):58-62.
5. Suresh V, Sojan J, Radhika NK, Asha VV. Anti-HBV activity of the different extracts from *Phyllanthus rheedei* Wight in cell culture based assay systems. *Journal of ethnopharmacology*. 2014; 156:309-15.
6. Krithika R, Jyothilakshmi V, Verma RJ. Phyllanthin inhibits CCl₄-mediated oxidative stress and hepatic fibrosis by down-regulating TNF- α /NF- κ B, and pro-fibrotic factor TGF- β 1 mediating inflammatory signaling. *Toxicology and industrial health*. 2016; 32(5):953-60.
7. Pradit W, Chomdej S, Nganvongpanit K, Ongchai S. Chondroprotective potential of *Phyllanthus amarus* Schum. & Thonn. in experimentally induced cartilage degradation in the explants culture model. *In Vitro*

- Cellular & Developmental Biology-Animal. 2015; 51(4):336-44.
8. Ilangkovan M, Jantan I, Bukhari SN. Phyllanthin from *Phyllanthus amarus* inhibits cellular and humoral immune responses in Balb/C mice. *Phytomedicine*. 2016; 23(12):1441-50.
 9. Murugaiyah V, Chan KL. Mechanisms of antihyperuricemic effect of *Phyllanthus niruri* and its lignan constituents. *Journal of ethnopharmacology*. 2009; 124(2):233-9.
 10. Gowrishanker B, Vivekanandan OS. In vivo studies of a crude extract of *Phyllanthus amarus* L. in modifying the genotoxicity induced in *Vicia faba* L. by tannery effluents. *Mutation Research/Genetic Toxicology*. 1994; 322(3):185-92.
 11. Rajakannan V, Sripathi MS, Selvanayagam S, Velmurugan D, Murthy UD, Vishwas M, Thyagarajan SP, Shanmuga Sundara Raj S, Fun HK. Phyllanthin from the plant *Phyllanthus amarus*. *Acta Crystallographica Section E: Structure Reports Online*. 2003; 59(2):o203-5.
 12. Row LR, Satyanarayana P, Rao GS. Crystalline constituents of euphorbiaceae—VI: The synthesis and absolute configuration of phyllanthin. *Tetrahedron*. 1967; 23(4):1915-8.
 13. Hanh ND, Sinchaipanid N, Mitrevej A. Physicochemical characterization of phyllanthin from *Phyllanthus amarus* Schum. et Thonn. *Drug development and industrial pharmacy*. 2014; 40(6):793-802.
 14. Khan S, Al-Qurainy F, Ram M, Ahmad S, Abdin MZ. Phyllanthin biosynthesis in *Phyllanthus amarus*: Schum and Thonn growing at different altitudes. *Journal of Medicinal Plants Research*. 2010; 4(1):041-8.
 15. Kandavel, D, Sekar, S. Impact of certain biotic and abiotic factors on phyllanthin and hypophyllanthin content of *Phyllanthus amarus* schum.& thonn. from three different habitats. *International Journal of Pharmacy and Pharmaceutical Sciences*. 2015;7(5) 258-265.
 16. Hanudin E, Wismarini H, Hertiani T, Hendro Sunarminto B. Effect of shading, nitrogen and magnesium fertilizer on phyllanthin and total flavonoid yield of *Phyllanthus niruri* in Indonesia soil. *Journal of Medicinal Plants Research*. 2012; 6(30):4586-92.
 17. Rai V, Mehrotra S. Chromium-induced changes in ultramorphology and secondary metabolites of *Phyllanthus amarus* Schum & Thonn.—an hepatoprotective plant. *Environmental monitoring and assessment*. 2008; 147(1):307-15.
 18. Rai V, Khatoon S, Bisht SS, Mehrotra S. Effect of cadmium on growth, ultramorphology of leaf and secondary metabolites of *Phyllanthus amarus* Schum. and Thonn. *Chemosphere*. 2005; 61(11):1644-50.
 19. Banerjee A, Chattopadhyay S. Effect of over-expression of *Linum usitatissimum* Pinoresinol Lariciresinol Reductase (LuPLR) gene in transgenic *Phyllanthus amarus*. *Plant Cell, Tissue and Organ Culture*. 2010; 103(3):315-23.
 20. Gupta AK. High herb, phyllanthin and hypophyllanthin yielding cultivar of *Phyllanthus amarus* 'cim-jeevan'. US Patent 2005/0050593 A1. Mar. 3, 2005.
 21. Thakur JS, Agarwal RK, Kharya MD. Immobilization mediated enhancement of phyllanthin and hypophyllanthin from *Phyllanthus amarus*. *Chinese Journal of Natural Medicines*. 2012; 10(3):207-12.
 22. Thakur JS, Kharya MD. Enhancing Hepatoprotective Bioactive's from *Phyllanthus Amarus* Through Immobilization. *International Journal of Bioscience, Biochemistry and Bioinformatics*. 2011; 1(4):302.
 23. Kumar PS, Mandahasan A, Kumar VS, Sanghai DB, Shreedhara CS, Setty MM. Production of Secondary Plant Metabolite Phyllanthin in *Phyllanthus niruri* Linn. by Leaf Tissue Culture. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*. 2012; 3(2):752-61.
 24. Nitnaware KM, Naik DG, Nikam TD. Thidiazuron-induced shoot organogenesis and production of hepatoprotective lignan phyllanthin and hypophyllanthin in *Phyllanthus amarus*. *Plant Cell, Tissue and Organ Culture (PCTOC)*. 2011; 104(1):101-10.
 25. Thakur JS, Agarwal RK, Kharya MD. Enhancing hepatoprotective bioactives of *Phyllanthus amarus* through immobilization by growth promoters and media changes. *Indian journal of pharmaceutical sciences*. 2011; 73(3):271.
 26. Kandavel, D, Sekar, S. Endophytic fungi from *Phyllanthus amarus* schum. & thonn. Capable of producing phyllanthin, hypophyllanthin and/or related compounds. *International Journal of Pharmacy and Pharmaceutical Sciences*. 2015; 7(5):253-257.
 27. Xavier JR, Gnanam R, Murugan MP, Pappachan A. Clonal propagation of *Phyllanthus amarus*: A hepatoprotector. *Pharmacognosy magazine*. 2012; 8(29):78.
 28. Chattopadhyay S, Ghosh AB. Establishment of cDNA Library and EST Analysis from Leaves of *Phyllanthus amarus*. *International Journal of Biochemistry Research & Review*. 2014; 4(1):1.
 29. Pereira RG, Nakamura RN, Rodrigues MV, Osorio-Tobón JF, Garcia VL, Martinez J. Supercritical fluid extraction of phyllanthin and niranthin from *Phyllanthus amarus* Schum. & Thonn. *The Journal of Supercritical Fluids*. 2017; 127:23-32.
 30. Patil AA, Bhusari SS, Shinde DB, Wakte PS. Optimization of process variables for phyllanthin extraction from *Phyllanthus amarus* leaves by supercritical fluid using a Box-Behnken experimental design followed by HPLC identification. *Acta pharmaceutica*. 2013; 63(2):193-207.
 31. Pereira RG, Garcia VL, Rodrigues MV, Martínez J. Extraction of lignans from *Phyllanthus amarus* Schum. & Thonn using pressurized liquids and low pressure methods. *Separation and Purification Technology*. 2016; 158:204-11.
 32. Jagtap S, Khare P, Mangal P, Kondepudi KK, Bishnoi M, Bhutani KK. Protective effects of phyllanthin, a lignan from *Phyllanthus amarus*, against progression of

- high fat diet induced metabolic disturbances in mice. *RSC Advances*. 2016; 6(63):58343-53.
33. Duc Hanh N, Mitrevej A, Sathirakul K, Peungvicha P, Sinchaipanid N. Development of phyllanthin-loaded self-microemulsifying drug delivery system for oral bioavailability enhancement. *Drug development and industrial pharmacy*. 2015; 41(2):207-17.
 34. Madhukiran P. Investigation of pharmacological activities, formulation of liposomes and pharmacokinetic studies of lignans from aerial parts of *phyllanthus amarus schum* and *thonn*. <http://hdl.handle.net/10603/28812>. 2013.
 35. Lam PL, Gambari R, Yip J, Yuen MC, Lam KH, Wong RS, Wang XW, Tang JC, Kok SH, Chui CH. Development of phyllanthin containing microcapsules and their improved biological activity towards skin cells and *Staphylococcus aureus*. *Bioorganic & medicinal chemistry letters*. 2012; 22(1):468-71.
 36. Sethiya NK, Shah P, Rajpara A, Nagar PA, Mishra SH. Antioxidant and hepatoprotective effects of mixed micellar lipid formulation of phyllanthin and piperine in carbon tetrachloride-induced liver injury in rodents. *Food & function*. 2015; 6(11):3593-603.
 37. Parhate VV, Rathore M, Rajput P. Study of *Phyllanthus Amarus* Plant Extract and Newly Synthesized Analogue of *Phyllanthin* on Induced Hepatotoxicity in Albino Rat. *International Journal of Chemical and Physical Sciences*. 2015; 4(SI):417-423.
 38. Anjaneyulu AS, Rao KJ, Row LR, Subrahmanyam C. Crystalline constituents of *euphorbiaceae*—XII: Isolation and structural elucidation of three new lignans from the leaves of *Phyllanthus niruri* Linn. *Tetrahedron*. 1973; 29(10):1291-8.
 39. Lerbscher JA, Rao KK, Trotter J. Iodophyllanthin. *Acta Crystallographica Section B: Structural Crystallography and Crystal Chemistry*. 1977; 33(4):1278-80.
 40. Sagar KS, Chang CC, Wang WK, Lin JY, Lee SS. Preparation and anti-HIV activities of retrojusticidin B analogs and azalignans. *Bioorganic & medicinal chemistry*. 2004; 12(15):4045-54.
 41. Kasthuri J, Kathiravan K, Rajendiran N. Phyllanthin-assisted biosynthesis of silver and gold nanoparticles: a novel biological approach. *Journal of Nanoparticle Research*. 2009; 11(5):1075-85.
 42. Ahmad N, Sharma S. Biomediated AgNPs from some ethnobotanical weeds—*Phyllanthus amarus*. *International Journal of Green Nanotechnology*. 2011; 3(2):109-17.
 43. Murugaiyah V, Chan KL. Analysis of lignans from *Phyllanthus niruri* L. in plasma using a simple HPLC method with fluorescence detection and its application in a pharmacokinetic study. *Journal of Chromatography B*. 2007; 852(1):138-44.
 44. Dhongade HJ, Chandewar AV. An in-vitro investigation of the antioxidant activity of *Phyllanthus amarus*. *International Journal of Biomedical and Advance Research*. 2013; 4(6):435-9.
 45. Thakur I, Bigoniya P. Radioprotective and free radicals scavenging activity of phyllanthin: Isolated from *Phyllanthus niruri*. *Int J Pharmacy Biol Sci*. 2014; 4:01-10.
 46. Krithika R, Mohankumar R, Verma RJ, Shrivastav PS, Mohamad IL, Gunasekaran P, Narasimhan S. Isolation, characterization and antioxidative effect of phyllanthin against CCl₄-induced toxicity in HepG2 cell line. *Chemico-biological interactions*. 2009; 181(3):351-8.
 47. Krithika R, Verma RJ, Shrivastav PS, Suguna L. Phyllanthin of standardized *phyllanthus amarus* extract attenuates liver oxidative stress in mice and exerts cytoprotective activity on human hepatoma cell line. *Journal of clinical and experimental hepatology*. 2011; 1(2):57-67.
 48. Krithika R, Verma RJ. Ameliorative effects of phyllanthin on carbon tetrachloride-induced hepatic oxidative damage in mice. *Asian Pacific Journal of Tropical Disease*. 2014; 4:S64-70.
 49. Jia R, Du JL, Cao LP, Liu YJ, Xu P, Yin GJ. Hepatoprotective and antioxidant effects of phyllanthin against carbon tetrachloride-induced liver injury in *Cyprinus carpio*. *Aquaculture international*. 2015; 23(4):883-93.
 50. Ooi KL, Loh SI, Sattar MA, Muhammad TS, Sulaiman SF. Cytotoxic, caspase-3 induction and in vivo hepatoprotective effects of phyllanthin, a major constituent of *Phyllanthus niruri*. *Journal of Functional Foods*. 2015; 14:236-43.
 51. U Bawankule D, Trivedi P, Pal A, Shanker K, Singh M, Sharma P, Khan F, K Maurya A, K Verma R, M Gupta M. Protective mechanism of lignans from *Phyllanthus amarus* against galactosamine/lipopolysaccharide-induced hepatitis: An in-vivo and in-silico studies. *Current topics in medicinal chemistry*. 2014; 14(8):1045-55.
 52. Chirdchupunseree H, Pramyothin P. Protective activity of phyllanthin in ethanol-treated primary culture of rat hepatocytes. *Journal of ethnopharmacology*. 2010; 128(1):172-6.
 53. Suresh V, Sojan J, Radhika NK, Asha VV. Anti-HBV activity of the different extracts from *Phyllanthus rheedii* Wight in cell culture based assay systems. *Journal of ethnopharmacology*. 2014; 156:309-15.
 54. Islam A, Selvan T, Mazumder UK, Gupta M, Ghosal S. Antitumour effect of phyllanthin and hypophyllanthin from *Phyllanthus amarus* against Ehrlich ascites carcinoma in mice. *Pharmacologyonline*. 2008; 2:796-807.
 55. Gowrishanker B, Vivekanandan OS. In vivo studies of a crude extract of *Phyllanthus amarus* L. in modifying the genotoxicity induced in *Vicia faba* L. by tannery effluents. *Mutation Research/Genetic Toxicology*. 1994; 322(3):185-92.
 56. Leite DF, Kassuya CA, Mazzuco TL, Silvestre A, de Melo LV, Rehder VL, Rumjanek VM, Calixto JB. The cytotoxic effect and the multidrug resistance reversing action of lignans from *Phyllanthus amarus*. *Planta medica*. 2006; 72(15):1353-8.
 57. Molska GR, Negri G, Paula-Freire LI, Araujo LP, Köhn DO, Basso AS, Carlini EA. *Phyllanthus amarus* does not affect hypernociception in experimental

- autoimmune encephalomyelitis. *Planta medica*. 2014 Mar; 80(04):277-82.
58. Kandhare AD, Ghosh P, Ghule AE, Zambare GN, Bodhankar SL. Protective effect of *Phyllanthus amarus* by modulation of endogenous biomarkers and DNA damage in acetic acid induced ulcerative colitis: Role of phyllanthin and hypophyllanthin. *Apollo Medicine*. 2013; 10(1):87-97.
 59. Mali SM, Sinnathambi A, Kapase CU, Bodhankar SL, Mahadik KR. Anti-arthritic activity of standardised extract of *Phyllanthus amarus* in Freund's complete adjuvant induced arthritis. *Biomedicine & Aging Pathology*. 2011; 1(3):185-90.
 60. Chouhan HS, Singh SK. Phytochemical analysis, antioxidant and anti-inflammatory activities of *Phyllanthus simplex*. *Journal of Ethnopharmacology*. 2011; 137(3):1337-44.
 61. Krithika R, Jyothilakshmi V, Prashantha K, Verma RJ. Mechanism of protective effect of phyllanthin against carbon tetrachloride-induced hepatotoxicity and experimental liver fibrosis in mice. *Toxicology mechanisms and methods*. 2015; 25(9):708-17.
 62. Krishnakumar, K.A., Hamza, K.M. and Asha, V.V., 2014. Antifibrotic activity of *Phyllanthus maderaspatensis* L. in Wistar rats. *Annals of Phytomedicine*. 2014; 3(1): 68-79.
 63. Inchoo M, Chirdchupunseree H, Pramyothin P, Jianmongkol S. Endothelium-independent effects of phyllanthin and hypophyllanthin on vascular tension. *Fitoterapia*. 2011; 82(8):1231-6.
 64. Ilangkovan M, Jantan I, Mesaik MA, Bukhari SN. Immunosuppressive effects of the standardized extract of *Phyllanthus amarus* on cellular immune responses in Wistar-Kyoto rats. *Drug design, development and therapy*. 2015; 9:4917.
 65. Ilangkovan M, Jantan I, Mohamad HF, Husain K, Abdul Razak AF. Inhibitory effects of standardized extracts of *Phyllanthus amarus* and *Phyllanthus urinaria* and their marker compounds on phagocytic activity of human neutrophils. *Evidence-Based Complementary and Alternative Medicine*. 2013.
 66. Yuandani IJ, Ilangkovan M, Husain K, Chan KM. Inhibitory effects of compounds from *Phyllanthus amarus* on nitric oxide production, lymphocyte proliferation, and cytokine release from phagocytes. *Drug Design, Development and Therapy*. 2016; 10:1935.
 67. Mazumder A, Mahato A, Mazumder R. Antimicrobial potentiality of *Phyllanthus amarus* against drug resistant pathogens. *Natural product research*. 2006; 20(04):323-6.
 68. H. Masrur, A. Ulfa and R. Ardiansyah. Pharmacopore modeling and molecular docking studies on *Phyllanthus niruri* as a target for diabetes mellitus. *Australian Journal of Basic and Applied Sciences*. 2015; 9(31):389-39.
 69. Murugaiyah V, Chan KL. Antihyperuricemic lignans from the leaves of *Phyllanthus niruri*. *Planta medica*. 2006; 72(14):1262-7.
 70. Sukhaphirom N, Vardhanabhuti N, Chirdchupunseree H, Pramyothin P, Jianmongkol S. Phyllanthin and hypophyllanthin inhibit function of P-gp but not MRP2 in Caco-2 cells. *Journal of Pharmacy and Pharmacology*. 2013; 65(2):292-9.
 71. Kushwaha SK, Dashora A, Dashora N, Patel JR, Kori ML. Acute oral toxicity studies of the standardized methanolic extract of *Phyllanthus amarus* Schum & Thonn. *Journal of Pharmacy Research*. 2013; 6(7):720-4.
 72. Islam A, Naskar S, Mazumder UK, Gupta M, Ghosal S. Estrogenic properties of phyllanthin and hypophyllanthin from *Phyllanthus amarus* against carbofuran induced toxicity in female rats. *Pharmacologyonline*. 2008; 3:1006-16.
 73. Joshi CS, Sanmuga Priya E. β -Glucuronidase Inhibitory Effect of Phenolic Constituents from *Phyllanthus amarus*. *Pharmaceutical Biology*. 2007; 45(5):363-5.
 74. Taesotikul T, Dumrongsakulchai W, Wattanachai N, Navinpipat V, Somanabandhu A, Tassaneeyakul W, Tassaneeyakul W. Inhibitory effects of *Phyllanthus amarus* and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition. *Drug metabolism and pharmacokinetics*. 2011; 26(2):154-61.